glp 1 gip triple agonist LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism GLP-1/GIP/Glucagon Triple Receptor Agonist -

Tirzepatide may have broader anti-inflammatory mechanisms

Additional experimental data support the protective role of GLP-1, including improved outcomes in DPP-4 knockout rats exposed to endotoxins and reduced mortality following GLP-1R activation (Perl et al., 2018

doi: 10.1016/j.ajpath.2019.10.008

Further, despite internal resistance at Novo, Knudsen initiated trials administering a higher dose of liraglutide (Saxenda) for the treatment of obesity

Recent research like the work happening at the University of Alabama at Birmingham (UAB) is helping explain why these medications are so effective and how they affect not just metabolism, but the brain itself